Search results for "610"

showing 10 items of 1353 documents

The future outlook on allergen immunotherapy in children: 2018 and beyond

2018

Abstract Allergen immunotherapy (AIT) is the only currently available immune-modifying and aetiological treatment for patients suffering from IgE-mediated diseases. In childhood, it represents a suitable therapeutic option to intervene during the early phases of respiratory allergic diseases such as rhino-conjunctivitis and asthma, which is when their progression may be more easily influenced. A growing body of evidence shows that oral immunotherapy represents a promising treatment option in children with persistent IgE- mediated food allergy. The efficacy of AIT is under investigation also in patients with extrinsic atopic dermatitis, currently with controversial results. Furthermore, AIT …

AllergyAllergen immunotherapymedicine.medical_specialtyAllergen-specific immunotherapy; Allergic rhinitis; Allergy; Children; Food allergy; IgE-mediated allergic diseases; Oral immunotherapy; Prevention; Sub-cutaneous immunotherapy; Sub-lingual immunotherapy; Child; Desensitization Immunologic; Food Hypersensitivity; Humans; Immunoglobulin E; Pediatrics Perinatology and Child HealthAllergySub-cutaneous immunotherapy610 Medicine & healthDiseaseReviewOral immunotherapyIgE-mediated allergic diseasesAllergic rhinitis03 medical and health sciences0302 clinical medicineQuality of life (healthcare)10183 Swiss Institute of Allergy and Asthma ResearchFood allergyFood allergyAllergic rhinitimedicineHumans2735 Pediatrics Perinatology and Child Health030212 general & internal medicineIntensive care medicineChildChildrenAsthmabusiness.industryPreventionlcsh:RJ1-570lcsh:PediatricsAtopic dermatitisImmunoglobulin Emedicine.diseaseSettore MED/38Allergen-specific immunotherapyRegimen030228 respiratory systemDesensitization ImmunologicIgE-mediated allergic diseasebusinessSub-lingual immunotherapyFood HypersensitivityItalian Journal of Pediatrics
researchProduct

MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

2018

mHealth, such as apps running on consumer smart devices is becoming increasingly popular and has the potential to profoundly affect healthcare and health outcomes. However, it may be disruptive and results achieved are not always reaching the goals. Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline using the best evidence-based approach to care pathways suited to real-life using mobile technology in allergic rhinitis (AR) and asthma multimorbidity. Patients largely use over-the-counter medications dispensed in pharmacies. Shared decision making centered around the patient and based on self-management should be the norm. Mobile Airways Sentinel networK (MASK), th…

AllergyHEALTH-ORGANIZATIONIMPACTRespiratory Medicine and Allergy[SDV]Life Sciences [q-bio]Allergic Rhinitis and its Impact on Asthma - ARIAReviewMASK - Mobile Airways Sentinel networK0302 clinical medicine610 Medical sciences MedicineApp; ARIA; Asthma; Care pathways; MASK; mHealth; Rhinitis; Immunology and Allergy; Immunology; Pulmonary and Respiratory MedicineHealth careMedicine and Health SciencesImmunology and Allergy030212 general & internal medicineAndroid (operating system)mHealthRinitisRhinitiComputingMilieux_MISCELLANEOUSLungmedicin och allergiRhinitisPRODUCTIVITY3. Good healthALLERGIC RHINITISmHealthRiniteCare pathwaysMedical emergencyLife Sciences & BiomedicinePulmonary and Respiratory MedicineSTRATEGIESMASKMASK study groupImmunologyMEDLINE610K-ANONYMITYPharmacy[object Object]Settore MED/10 - Malattie Dell'Apparato RespiratorioVALIDATIONMACVIA-ARIA03 medical and health sciencesmedicineMobile technologyTECHNOLOGYApp -MASKApp ; ARIA ; Asthma ; Care pathways ; MASK ; mHealth ; RhinitisARIA; App; Asthma; Care pathways; MASK; Rhinitis; mHealthAsmaAsthmaCare pathwayScience & TechnologyARIAbusiness.industryApp; ARIA; Asthma; Care pathways; MASK; mHealth; RhinitisSettore MED/09 - MEDICINA INTERNACorrectionGuidelineRC581-607medicine.diseaseAsthma030228 respiratory systemImmunologic diseases. AllergybusinessAppEUROPEAN COUNTRIES[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Nasal IgE in subjects with allergic and non-allergic rhinitis

2020

Abstract Purpose The prevalence of "ocal allergic rhinitis" within individuals suffering from perennial rhinitis remains uncertain, and patients usually are diagnosed with non-allergic rhinitis. The aim of this study was to evaluate the prevalence of a potential "local allergic rhinitis" in subjects suffering from non-allergic rhinitis in a non-selected group of young students. Methods 131 students (age 25.0 ± 5.1 years) with a possible allergic rhinitis and 25 non-allergic controls without rhinitis symptoms (age 22.0 ± 2.0 years) were recruited by public postings. 97 of 131 students with rhinitis were tested positive (≥3 mm) to prick testing with 17 frequent allergens at visit 1. Twenty-fo…

AllergyNon-allergic rhinitismedicine.medical_treatmentImmunoglobulin EAR + HDM allergic rhinitis with house dust mite allergyAllergic rhinitisHDM house dust miteNPT nasal provocation testsAR allergic rhinitis0302 clinical medicineISAAC International Study of Asthma and Allergies in Childhood questionnaireNARES non-allergic rhinitis with eosinophilia-syndromeMedicine and Health SciencesImmunology and Allergy030223 otorhinolaryngologyeducation.field_of_studybiologymedicine.diagnostic_testRadioallergosorbent testsIgE allergen-specific IgENon-allergicD1 Dermatophagoides pteronyssinusPREVALENCED2 Dermatophagoides farinaeLAR local allergic rhinitisPROVOCATION TESTSPulmonary and Respiratory Medicinelcsh:Immunologic diseases. AllergyLOCAL IGEImmunologyPopulationPATHOPHYSIOLOGYNon-allergic-rhinitisLocal allergic rhinitisGCP Good Clinical PracticeDIAGNOSISNasal provocation testArticleSECRETIONS03 medical and health sciencesFEV1/FVC ratiorhinitismedicineddc:610educationHouse dust mitebusiness.industryFEV1 forced expiratory volume in one secondRAST Radioallergosorbent Testbiology.organism_classificationmedicine.disease030228 respiratory systemHouse dust mite allergyPNIF peak nasal inspiratory flowImmunologyFVC forced vital capacitybiology.proteinbusinessSD standard deviationlcsh:RC581-607Local IgESPT skin prick testWorld Allergy Organization Journal
researchProduct

The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update

2014

This guideline is the result of a systematic literature review using the 'Grading of Recommendations Assessment, Development and Evaluation' (GRADE) methodology and a structured consensus conference held on 28 and 29 November 2012, in Berlin. It is a joint initiative of the Dermatology Section of the European Academy of Allergy and Clinical Immunology (EAACI), the EU-funded network of excellence, the Global Allergy and Asthma European Network (GA(2)LEN), the European Dermatology Forum (EDF), and the World Allergy Organization (WAO) with the participation of delegates of 21 national and international societies. Urticaria is a frequent, mast cell-driven disease, presenting with wheals, angioe…

Allergymedicine.medical_specialtyhivesImmunologylcsh:Medicine610 Medicine & healthDermatologyDiseaseurticariaimmune system diseaseslcsh:DermatologyHumansImmunology and AllergyMedicinemedia_common.cataloged_instanceEuropean unionskin and connective tissue diseaseswhealAsthmamedia_common2403 ImmunologyAcute urticariaAngioedemabusiness.industryangioedemalcsh:RConsensus conferenceangioedema; consensus; hives; urticaria; wheal; Humans; Urticaria10177 Dermatology ClinicGuidelinelcsh:RL1-803angioedema consensus hives urticaria wheal CHRONIC IDIOPATHIC URTICARIA QUALITY-OF-LIFE SERUM SKIN-TEST DELAYED PRESSURE URTICARIA DOSE INTRAVENOUS IMMUNOGLOBULIN ANTIIMMUNOGLOBULIN-E THERAPY RESISTANT CHRONIC URTICARIA RANDOMIZED CONTROLLED-TRIAL ULTRAVIOLET-B PHOTOTHERAPY WORLD-HEALTH-ORGANIZATIONmedicine.diseaseDermatologySystematic reviewconsensusFamily medicine2723 Immunology and Allergymedicine.symptombusinessAllergy
researchProduct

Faldaprevir (BI 201335), BI 207127 and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results

2013

Background Faldaprevir (BI 201335) and deleobuvir (BI 207127) are direct-acting antiviral agents under development for the treatment of chronic HCV infection. This article describes the final results of the Phase Ib SOUND-C1 study that evaluated the interferon-free oral combination of faldaprevir, deleobuvir and ribavirin in 32 treatment-naive patients infected with HCV genotype 1. Methods Patients were randomized to receive deleobuvir 400 mg ( n=15) or 600 mg ( n=17) three times daily plus faldaprevir 120 mg once daily and weight-based ribavirin for 4 weeks. Interferon-free therapy was followed by response-guided faldaprevir plus pegylated interferon-α2a/ribavirin to week 24 or 48. Results…

Aminoisobutyric AcidsProline[SDV]Life Sciences [q-bio]610 Medicine & healthHepacivirusAntiviral AgentsDrug Administration SchedulePolyethylene GlycolsTherapy naive03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHcv genotype 1LeucineRibavirinMedicine2736 Pharmacology (medical)Pharmacology (medical)Oral therapy030304 developmental biologyPharmacology0303 health sciencesbusiness.industryRibavirinDeleobuvirInterferon-alpha2725 Infectious DiseasesHepatitis C ChronicViral LoadVirologyRecombinant Proteins3. Good healthThiazolesInfectious DiseasesTreatment Outcome10219 Clinic for Gastroenterology and Hepatology3004 PharmacologychemistryAcrylatesFaldaprevirQuinolines030211 gastroenterology & hepatologyBenzimidazolesDrug Therapy CombinationbusinessOligopeptides
researchProduct

Loss of density-dependence and incomplete control by dominant breeders in a territorial species with density outbreaks

2011

Abstract Background A territory as a prerequisite for breeding limits the maximum number of breeders in a given area, and thus lowers the proportion of breeders if population size increases. However, some territorially breeding animals can have dramatic density fluctuations and little is known about the change from density-dependent processes to density-independence of breeding during a population increase or an outbreak. We suggest that territoriality, breeding suppression and its break-down can be understood with an incomplete-control model, developed for social breeders and social suppression. Results We studied density dependence in an arvicoline species, the bank vole, known as a terri…

Animal breedingBiologyTerritorialitydominancePopulation densityterritoriaalisuusEnvironmental Science(all)ddc:570AnimalsdominanssiPopulation growthddc:610territorialitInstitut für Biochemie und BiologieQH540-549.5reproductive and urinary physiologyEcology Evolution Behavior and SystematicsGeneral Environmental SciencePopulation DensityBehavior AnimalEcologyArvicolinaeEcologyReproductionPopulation sizefood and beveragesOutbreakDensity dependenceFemaleTerritorialitysosiaalinen kontrolliResearch ArticleBMC Ecology
researchProduct

Glycogen synthase 2 is a novel target gene of peroxisome proliferator-activated receptors.

2007

International audience; Glycogen synthase 2 (Gys-2) is the ratelimiting enzyme in the storage of glycogen in liver and adipose tissue, yet little is known about regulation of Gys-2 transcription. The peroxisome proliferator-activated receptors (PPARs) are transcription factors involved in the regulation of lipid and glucose metabolism and might be hypothesized to govern glycogen synthesis as well. Here, we show that Gys-2 is a direct target gene of PPARalpha, PPARbeta/delta and PPARgamma. Expression of Gys-2 is significantly reduced in adipose tissue of PPARalpha-/-, PPARbeta/delta-/- and PPARgamma+/- mice. Furthermore, synthetic PPARbeta/delta, and gamma agonists markedly up-regulate Gys-2…

Animals; Chromatin/ultrastructure; DNA Primers; Gene Expression Regulation Enzymologic; Glycogen Synthase/genetics; Hepatocytes/enzymology; Hepatocytes/physiology; Mice; Mice Knockout; Peroxisome Proliferator-Activated Receptors/deficiency; Peroxisome Proliferator-Activated Receptors/genetics; Polymerase Chain Reaction; RNA/genetics; RNA/isolation & purification; Rats; Transcription GeneticTranscription GeneticPeroxisome proliferator-activated receptorMESH : HepatocytesPPREPolymerase Chain Reactionadipose-tissuePPARMESH: HepatocytesMice0302 clinical medicineMESH: Animals610 Medicine & healthchemistry.chemical_classificationRegulation of gene expression0303 health sciencesGlycogenglycogen-synthaseChromatinGlycogen Synthase030220 oncology & carcinogenesisMESH : DNA PrimersmicroarrayMESH: DNA Primersmedicine.medical_specialtyHealth aging / healthy living [IGMD 5]fatty-acid oxidationliverGene Expression Regulation EnzymologicMESH: Chromatin03 medical and health sciencesskeletal-muscleGlycogen synthaseMolecular Biology[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyHNF4αVLAGPharmacologybeta/deltaMESH: Polymerase Chain Reactionresponse elementsMESH : Peroxisome Proliferator-Activated ReceptorsEndocrinologychemistryMicrobial pathogenesis and host defense [UMCN 4.1]Response elementPeroxisome Proliferator-Activated ReceptorsAdipose tissueMESH: Peroxisome Proliferator-Activated Receptorsin-vivoMESH: Mice KnockoutTransactivationchemistry.chemical_compoundVoeding Metabolisme en GenomicaMESH : RNAMESH : Polymerase Chain ReactionMice KnockoutMESH : ChromatinMESH : RatsMESH: Gene Expression Regulation EnzymologicMetabolism and Genomicsadipose tissueMetabolisme en GenomicaMolecular MedicineNutrition Metabolism and GenomicsMESH : Glycogen SynthaseResearch ArticleMESH: Ratsglycogen synthase 2610 Medicine & healthBiologyMESH : Gene Expression Regulation EnzymologicCellular and Molecular NeuroscienceVoedingMESH: RNAInternal medicineMESH : MicemedicineAnimals[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyTranscription factorMESH: Micealpha ppar-alpha030304 developmental biologyNutritionDNA PrimersMESH: Glycogen SynthaseMESH: Transcription GeneticMESH : Transcription GeneticCell BiologyRatsgene transcriptionbiology.proteinHepatocytesRNAMESH : Mice KnockoutgammaMESH : Animalsmetabolism
researchProduct

Emotion regulation in adolescents with anorexia and bulimia nervosa: Differential use of adaptive and maladaptive strategies compared to healthy adol…

2021

Objective: Adolescents with anorexia (AN) and bulimia nervosa (BN) often struggle with emotion regulation (ER). These difficulties have predominantly been assessed across emotions, without considering adaptive and maladaptive ER separately.We compared adolescents with AN or BN to healthy adolescents (HCs) regarding the adaptive and maladaptive ER of three emotions. Methods: A treatment-seeking sample of 197 adolescents (atypical/full-threshold AN: N = 118, atypical/full-threshold BN: N = 32; HC: N = 47) reported emotion-specific ER with the FEEL-KJ questionnaire. Mixed models were calculated for adaptive and maladaptive ER to assess differences between emotions (anxiety, anger, sadness) and…

Anorexia NervosaAdolescentmedia_common.quotation_subjectEmotions610 MedizinAnorexiaAngerbehavioral disciplines and activities610 Medical sciencesmental disordersPost-hoc analysismedicineHumansBulimia Nervosamedia_commonbusiness.industryBulimia nervosamedicine.diseaseAnorexiaEmotional RegulationSadnessPsychiatry and Mental healthEating disordersAnorexia nervosa (differential diagnoses)Anxietymedicine.symptombusinessClinical psychologyInternational Journal of Eating Disorders
researchProduct

Alianzas, ambiciones y ascenso de dos familias de la élite concejil orensana en 1680-1746: los Armada y Araúxo, y los Salgado y Gundín

2020

Antonio 181 201UNESCO::HISTORIARevista de historia moderna 561078 2020 46 7649197 Alianzas [0210-9093 553 Estudis]los Armada y Araúxo [ambiciones y ascenso de dos familias de la élite concejil orensana en 1680-1746]:HISTORIA [UNESCO]y los Salgado y Gundín Presedo Garazoambiciones y ascenso de dos familias de la élite concejil orensana en 1680-1746: los Armada y Araúxo0210-9093 553 Estudis: Revista de historia moderna 561078 2020 46 7649197 Alianzas
researchProduct

CardioPulse: developments in the treatment of aortic aneurysms in 2014

2015

Since the introduction of EndoVascular Aortic Repair (EVAR) for the treatment of abdominal aortic aneurysms (AAA) more than 20 years ago, the technique has evolved rapidly, from tubular grafts for fairly simple abdominal aortic anatomy, to bifurcated, fenestrated, branched, or parallel grafts for complex aortic aneurysms, no longer confined to the infrarenal abdominal aorta.

Aortic Aneurysm ThoracicAortic RuptureEndovascular ProceduresBiomedical Technology610 Medicine & healthEquipment DesignSettore MED/22 - Chirurgia Vascolare2705 Cardiology and Cardiovascular MedicineBlood Vessel Prosthesis10020 Clinic for Cardiac SurgeryBlood Vessel Prosthesis ImplantationHumansaortic aneurysmAortic Aneurysm Abdominal
researchProduct